Johnson & Johnson (NYSE: JNJ) is focusing on the next iteration of its business -- one that investors hope creates a lot more growth than in years past. The company spun off its consumer health business last year, and with just two main segments moving forward -- medical devices and innovative medicines -- J&J could be in a good position to accelerate its growth rate.

But investors don't appear to be convinced.

Year to date, the stock price is down 6.3% and has underperformed the S&P 500, which is up by 14.6% thus far. It's currently trading near its 52-week low, and it pays a fairly attractive dividend, which yields 3.3%. Is now a good time to buy this top healthcare stock?

Continue reading

Source Fool.com